Marché de la dégénérescence maculaire liée à l’âge (DMLA) en Asie-Pacifique – Tendances et prévisions du secteur jusqu’en 2029

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché de la dégénérescence maculaire liée à l’âge (DMLA) en Asie-Pacifique – Tendances et prévisions du secteur jusqu’en 2029

  • Pharmaceutical
  • Publish Reports
  • Jun 2022
  • Asia-Pacific
  • 350 Pages
  • Nombre de tableaux : 90
  • Nombre de figures : 33

>Marché de la dégénérescence maculaire liée à l'âge (DMLA) en Asie-Pacifique, par type (DMLA sèche et DMLA humide ), utilisateur final (hôpitaux, cliniques spécialisées, centres de chirurgie ambulatoire, soins à domicile et autres), canal de distribution (appels d'offres directs et ventes au détail) Tendances de l'industrie et prévisions jusqu'en 2029.

Marché de la dégénérescence maculaire liée à l'âge (DMLA) en Asie-Pacifique

Analyse et perspectives du marché

Le marché de la dégénérescence maculaire liée à l'âge (DMLA) en Asie-Pacifique est stimulé par des facteurs tels que l'augmentation de la population gériatrique, l'augmentation de la prévalence de la maladie et l'augmentation des produits en développement qui augmentent sa demande ainsi que l'augmentation des investissements dans la recherche et le développement conduisent à la croissance du marché. Actuellement, les dépenses de santé ont augmenté dans les pays développés et émergents, ce qui devrait créer un avantage concurrentiel pour les fabricants pour développer des produits nouveaux et innovants.

Marché de la dégénérescence maculaire liée à l'âge (DMLA) en Asie-Pacifique

La prévalence de la dégénérescence maculaire liée à l'âge devrait augmenter dans les pays développés en raison du vieillissement de la population et de l'augmentation de l'espérance de vie. On estime que près de 60 % des patients souffrent d'une déficience visuelle grave survenant peu après la naissance. Cette maladie entraîne une vision centrale floue dans l'œil du patient. La demande de traitement et de diagnostic de la dégénérescence maculaire liée à l'âge (DMLA) a augmenté davantage dans les pays développés. Cependant, le coût élevé associé au traitement et à la procédure ainsi que les réglementations gouvernementales strictes pour l'approbation des produits devraient entraver la croissance du marché de la dégénérescence maculaire liée à l'âge (DMLA).

Le marché de la dégénérescence maculaire liée à l'âge (DMLA) en Asie-Pacifique est favorable et vise à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché de la dégénérescence maculaire liée à l'âge (DMLA) en Asie-Pacifique connaîtra une croissance de 7,2 % au cours de la période de prévision de 2022 à 2029.

Rapport métrique

Détails

Période de prévision

2022 à 2029

Année de base

2021

Année historique

2020 (personnalisable de 2019 à 2014)

Unités quantitatives

Chiffre d'affaires en millions USD

Segments couverts

Par type (DMLA sèche et DMLA humide), utilisateur final (hôpitaux, cliniques spécialisées, centres de chirurgie ambulatoire, soins à domicile et autres), canal de distribution (appels d'offres directs et ventes au détail), tendances et prévisions du secteur jusqu'en 2029

Pays couverts

Par pays (Chine, Inde, Corée du Sud, Australie, Singapour, Malaisie, Thaïlande, Indonésie, Philippines, Vietnam, reste de l'Asie-Pacifique) Tendances et prévisions de l'industrie jusqu'en 2029

Acteurs du marché couverts

Novartis AG, Bayer AG, Astellas Pharma Inc., Ionis Pharmaceutics, Johnson & Johnson Services, Inc., entre autres

Définition du marché

Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.

The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.

Asia-Pacific Age-Related Macular Degeneration (AMD) Disease Market Dynamics

Drivers

  • Rising geriatric population

The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the Asia-Pacific incidence of early AMD.Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.

Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the Asia-Pacific age-related macular degeneration (AMD) disease market growth.

  • Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease

The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.

Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the Asia-Pacific age-related macular degeneration (AMD) disease market growth.

Opportunity

  •  Rising Research and Development 

Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country Asia-Pacific. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.

The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the Asia-Pacific age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Asia-Pacific age-related macular degeneration (AMD) disease market.

Restraint/Challenge

  • High cost of aesthetic surgical procedures

The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the Asia-Pacific age-related macular degeneration (AMD) disease market growth.

Recent Developments

  • In January 2022, Genentech, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet AMD and DME.This will help the company to commercialize the product in the market in the forecast period.
  • In April 2022, Graybug Vision Inc. announced that the company has presented a poster presentation preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and evaluation of drug in the market.

Asia-Pacific Age-related Macular Degeneration (AMD) Disease Market Segmentation

Asia-Pacific age-related macular degeneration (AMD) disease market is categorized into is categorized into three notable segments which are based on type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

  • Dry AMD
  • Wet AMD

On the basis of type, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD.

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

On the basis of end user, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.

Distribution Channel

  • Retail Sales
  • Direct Tender

Marché de la maladie de dégénérescence maculaire liée à l'âge (DMLA)

On the basis of distribution channel, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into retail sales and direct tender.

Age-related macular degeneration (AMD) disease market Regional Analysis/Insights

The age-related macular degeneration (AMD) disease market is analysed and market size insights and trends are provided by type, end user and distribution channel as referenced above.

The countries covered in the age-related macular degeneration (AMD) disease report are China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.

China is expected to dominate due to increasing technological advancement in the developing areas.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Analyse du paysage concurrentiel et des parts de marché de la dégénérescence maculaire liée à l'âge (DMLA)

Le paysage concurrentiel du marché de la maladie de dégénérescence maculaire liée à l'âge (DMLA) en Asie-Pacifique fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Asie-Pacifique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché de la maladie de dégénérescence maculaire liée à l'âge (DMLA).

 Certains des acteurs du marché sont Novartis AG, Bayer AG, Astellas Pharma Inc., Ionis Pharmaceutics, Johnson & Johnson Services, Inc, entre autres.

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse de la part de marché Asie-Pacifique par rapport à la région et des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION

6.1.2 INCREASING GERIATRIC POPULATION

6.1.3 INCREASE IN PIPELINE PRODUCTS

6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS

6.2 RESTRAINTS

6.2.1 HIGH COST OF TREATMENT AND PROCEDURES

6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS

6.3 OPPORTUNITIES

6.3.1 INCREASING RESEARCH AND DEVELOPMENT

6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD

6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT

6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)

6.4 CHALLENGES

6.4.1 LIMITED ACCESS TO TREATMENT

6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS

7 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE

7.1 OVERVIEW

7.2 DRY AMD

7.3 WET AMD

7.3.1 MEDICATIONS

7.3.2 ANTI-VEGF THERAPY

7.3.3 GENE THERAPY

7.3.4 SURGERY

8 ASIA PACIFIC AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 SPECIALTY CLINICS

8.4 AMBULATORY SURGICAL CENTERS

8.5 HOME HEALTHCARE

8.6 OTHERS

9 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 RETAIL SALES

9.2.1 HOSPITAL PHARMACIES

9.2.2 RETAIL PHARMACIES

9.2.3 OTHERS

9.3 DIRECT TENDER

10 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION

10.1 ASIA-PACIFIC

10.1.1 CHINA

10.1.2 JAPAN

10.1.3 INDIA

10.1.4 SOUTH KOREA

10.1.5 AUSTRALIA

10.1.6 SINGAPORE

10.1.7 THAILAND

10.1.8 INDONESIA

10.1.9 PHILIPPINES

10.1.10 MALAYSIA

10.1.11 VIETNAM

10.1.12 REST OF ASIA-PACIFIC

11 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

12 SWOT ANALYSIS

13 COMPANY PROFILE

13.1 NOVARTIS AG

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 COMPANY SHARE ANALYSIS

13.1.4 PRODUCT PORTFOLIO

13.1.5 RECENT DEVELOPMENT

13.1.5.1 AGREEMENT

13.2 GENENTECH, INC.

13.2.1 COMPANY SNAPSHOT

13.2.2 COMPANY SHARE ANALYSIS

13.2.3 PRODUCT PORTFOLIO

13.2.4 RECENT DEVELOPMENT

13.3 BAYER AG

13.3.1 COMPANY SNAPSHOT

13.3.2 REVENUE ANALYSIS

13.3.3 COMPANY SHARE ANALYSIS

13.3.4 PRODUCT PORTFOLIO

13.3.5 RECENT DEVELOPMENT

13.4 ADVERUM BIOTECHNOLOGIES, INC.

13.4.1 COMPANY SNAPSHOT

13.4.2 REVENUE ANALYSIS

13.4.3 PRODUCT PORTFOLIO

13.4.4 RECENT DEVELOPMENT

13.5 ASTELLAS PHARMA INC.

13.5.1 COMPANY SNAPSHOT

13.5.2 REVENUE ANALYSIS

13.5.3 PRODUCT PORTFOLIO

13.5.4 RECENT DEVELOPMENT

13.6 GRAYBUG VISION INC.

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENT

13.7 GENSIGHT BIOLOGICS

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENTS

13.7.4.1 EVENT

13.7.4.2 AWARD

13.8 IONIS PHARMACEUTICALS

13.8.1 COMPANY SNAPSHOT

13.8.2 REVENUE ANALYSIS

13.8.3 PRODUCT PORTFOLIO

13.8.4 RECENT DEVELOPMENT

13.8.4.1 EVENT

13.9 IVERIC BIO

13.9.1 COMPANY SNAPSHOT

13.9.2 PRODUCT PORTFOLIO

13.9.3 RECENT DEVELOPMENT

13.1 JOHNSON &JOHNSON SERVICES, INC.

13.10.1 COMPANY SNAPSHOT

13.10.2 REVENUE ANALYSIS

13.10.3 PRODUCT PORTFOLIO

13.10.4 RECENT DEVELOPMENT

13.10.4.1 COLLABORATION

13.11 KODIAK SCIENCES INC.

13.11.1 COMPANY SNAPSHOT

13.11.2 PRODUCT PORTFOLIO

13.11.3 RECENT DEVELOPMENT

13.12 MEIRAGTX LIMITED

13.12.1 COMPANY SNAPSHOT

13.12.2 PRODUCT PORTFOLIO

13.12.3 RECENT DEVELOPMENTS

13.12.3.1 EVENTS

13.12.3.2 AWARD

13.12.3.3 COLLABORATION

13.13 OCUGEN INC.

13.13.1 COMPANY SNAPSHOT

13.13.2 PRODUCT PORTFOLIO

13.13.3 RECENT DEVELOPMENTS

13.13.3.1 INVESTMENT

13.13.3.2 CLINICAL TRIAL

13.14 PIXIUM VISION

13.14.1 COMPANY SNAPSHOT

13.14.2 REVENUE ANALYSIS

13.14.3 PRODUCT PORTFOLIO

13.14.4 RECENT DEVELOPMENT

13.14.4.1 AWARD

13.15 REGENXBIO INC.

13.15.1 COMPANY SNAPSHOT

13.15.2 PRODUCT PORTFOLIO

13.15.3 RECENT DEVELOPMENTS

13.15.3.1 EVENT

13.15.3.2 COLLABORATION

13.15.3.3 CERTIFICATION

14 QUESTIONNAIRE

15 RELATED REPORTS

Liste des tableaux

TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION

TABLE 2 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 18 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 20 ASIA-PACIFIC MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 22 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 23 ASIA-PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 24 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 CHINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 26 CHINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 27 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 CHINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 30 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 JAPAN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 JAPAN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 JAPAN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 36 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 INDIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 INDIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 INDIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 SOUTH KOREA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 SOUTH KOREA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 46 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 47 SOUTH KOREA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 48 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 AUSTRALIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 AUSTRALIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 AUSTRALIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 54 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 SINGAPORE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 SINGAPORE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 SINGAPORE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 60 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 THAILAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 THAILAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 THAILAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 66 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 INDONESIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 INDONESIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 INDONESIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 PHILIPPINES WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 PHILIPPINES MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 77 PHILIPPINES RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 MALAYSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 MALAYSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 MALAYSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 85 VIETNAM WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 VIETNAM MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 88 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 89 VIETNAM RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 90 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

Liste des figures

FIGURE 1 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: END USER COVERAGE GRID

FIGURE 10 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DRY AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN 2022 & 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET

FIGURE 16 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2021

FIGURE 17 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 18 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2021

FIGURE 21 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 22 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, CAGR (2022-2029)

FIGURE 23 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, LIFELINE CURVE

FIGURE 24 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 25 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 26 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 27 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 28 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SNAPSHOT (2021)

FIGURE 29 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021)

FIGURE 30 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2022 & 2029)

FIGURE 31 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021 & 2029)

FIGURE 32 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE (2022-2029)

FIGURE 33 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY SHARE 2021 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.